Follow us on Twitter
twitter icon@FreshPatents


Type 1 Diabetes patents

      

This page is updated frequently with new Type 1 Diabetes-related patent applications.




 Inhibition of gliadin peptides patent thumbnailInhibition of gliadin peptides
Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided.
Alba Therapeutics Corporation


 Compositions and methods for treating type 1 and type 2 diabetes and related disorders patent thumbnailCompositions and methods for treating type 1 and type 2 diabetes and related disorders
The invention features compositions comprising in vitro generated beta cells capable of glucose-stimulated insulin secretion, methods of inducing beta cell maturation from embryonic or induced pluripotent stem cell-derived beta-like cells, and methods of using in vitro generated beta cells for the treatment of type 1 diabetes, type 2 diabetes, or a related disorder.. .
Salk Institute For Biological Studies


 Nutritional compositions comprising a lipophilic active ingredient patent thumbnailNutritional compositions comprising a lipophilic active ingredient
Disclosed embodiments provide methods and compositions for improving the metabolic health of consumers. Bovine beta-casein, a major component of milk from cattle, has many genetic variants.
Abbott Laboratories


 Neo-islets comprising stem and islet cells and treatment of diabetes mellitus therewith patent thumbnailNeo-islets comprising stem and islet cells and treatment of diabetes mellitus therewith
Described are neo-islets comprising: a) dedifferentiated islet cells and mesenchymal and/or adipose stem cells; or b) redifferentiated islet cells and mesenchymal and/or adipose stem cells where the cells have been treated so as to facilitate redifferentiation. Further described herein are methods of generating neo-islets, the methods comprising: culturing a) dedifferentiated islet cells and mesenchymal and/or adipose stem cells; or b) redifferentiated islet cells and mesenchymal and/or adipose stem cells; on a surface that promotes the formation of cell clusters.
Symbiocelltech, Llc


 Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling patent thumbnailMethods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
The invention relates to the identification of new therapeutic methods for the fgf21 polypeptide or protein, or mutants, variants, and fusions thereof, for instance, in treating metabolic diseases associated defects in insulin signaling (e.g. Insulin receptor mutation disorders (insr disorders) and/or autoimmune insulin receptor disorders (type b insulin resistance)), defects in insulin production such as type 1 diabetes mellitus, mixed dyslipidemia, nonalcoholic fatty liver disease (nafld), and other metabolic disorders, and various lipodystrophies such as hiv-haart induced partial-lipodystrophy, and in reducing the mortality and morbidity of critically ill patients..
Novartis Ag


 Substituted pyridazines as prostacyclin receptor modulators patent thumbnailSubstituted pyridazines as prostacyclin receptor modulators
Cyclohexane derivatives of formula ia and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd)..
Arena Pharmaceuticals, Inc.


 Methods of measuring antigen-specific t cells patent thumbnailMethods of measuring antigen-specific t cells
Provided herein are methods and kits for assaying antigen-specific t cell responses, such as rare autoantigen-specific t cell responses, by measuring a level of ip-10 in a sample from a subject having or suspected of having an autoimmune disease, an allergy, an infectious disease or condition, or an adverse immune condition caused by administration of an isolated, recombinant or synthetic protein or peptide. Also provided herein are methods and kits for assaying a t cell response to an antigen peptide, such as an islet autoantigen peptide, such as measuring a t cell response to at least one antigen peptide, such as an islet autoantigen peptide, in a sample from a subject, such as one having or suspected of having type 1 diabetes (tid), celiac disease or both..
Immusant, Inc.


 Genetic alterations on chromosome 16 and methods of use thereof for the diagnosis and treatment of type 1 diabetes patent thumbnailGenetic alterations on chromosome 16 and methods of use thereof for the diagnosis and treatment of type 1 diabetes
Compositions and methods for the detection and treatment of t1d are provided.. .
The Children's Hospital Of Philadelphia


 Treatment of diabetes type 1 using glp-1 and anti-il-21 patent thumbnailTreatment of diabetes type 1 using glp-1 and anti-il-21
The present invention relates to use of a glp-1 agonist and an anti-il-2 antibody in treatment and/or prevention of type 1 diabetes.. .
Novo Nordisk A/s


 Stimulation via tlr4/md-2 to reverse type 1 diabetes patent thumbnailStimulation via tlr4/md-2 to reverse type 1 diabetes
Disclosed are methods and compositions for treating type i diabetes in a subject. Agents selected from a tlr4 agonist, a tlr4/md-2 agonist, or a combination thereof may be used in the disclosed methods and compositions.
University Of Cincinnati


Pharmaceutical composition, methods for treating and uses thereof

The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using a sglt-2 inhibitor. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions..
Boehringer Ingelheim International Gmbh

Immunomodulatory therapy for type 1 diabetes mellitus autoimmunity

A composition for treating type 1 diabetes mellitus autoimmunity can include a therapeutically effective amount of two or more overlapping fragments of preproinsulin and a pharmaceutically acceptable carrier, wherein at least one of the polypeptide fragments is antigenic.. .

Method to detect autoantibody reactivity for deamidated insulin autoantigen in diabetes

Provided herein are epitopes and mimotopes thereof useful in the diagnosis and treatment of type 1 diabetes (t1d), as well as antibodies recognizing such epitopes, and diagnostics, therapeutics, kits, and methods of use thereof.. .
Northwestern University

Compositions for preserving insulin-producing cells and insulin production and treating diabetes

Nuclear transport modifiers such as csn50 and csn50.1, afford in vivo islet protection following a 2-day course of intense treatment in autoimmune diabetes-prone, non-obese diabetic (nod) mice, a widely used model of type 1 diabetes (t1d), which resulted in a diabetes-free state for one year without apparent toxicity and the need to use insulin. Csn50 precipitously reduces the accumulation of islet-destructive autoreactive lymphocytes while enhancing activation-induced cell death of t and b lymphocytes derived from nod mice.
Vanderbilt University

Combination of metabolic bio-energetic and nutra-epigentic regulators, nutraceutical compounds in conventional and nanotechnologies combination to revert and prevent the chronic damage accelerated cellullar senescence produced by diabetis and other degenerative chronic complex diseases

The invention relates to compounds of natural origin and their pharmaceutically acceptable and active mixture to decrease glucose, cholesterol, uric acid, and body fat the high levels, cytoprotection of damaged organs, activation of metabolism and cell proliferation. It is exemplified with the pharmaceutical composition comprising a pharmaceutically effective amount of the compounds of formulation i, and its method on in vitro and in vivo systems.

Individualized multiple-day simulation model of type 1 diabetic patient decision-making for developing, testing and optimizing insulin therapies driven by glucose sensors

A mathematical model of type 1 diabetes (t1d) patient decision-making can be used to simulate, in silico, realistic glucose/insulin dynamics, for several days, in a variety of subjects who take therapeutic actions (e.g. Insulin dosing) driven by either self-monitoring blood glucose (smbg) or continuous glucose monitoring (cgm).
Dexcom, Inc.

Particle formulations of all-trans retinoic acid and transforming growth factor beta for the treatment of type 1 diabetes mellitus

Particle formulations are disclosed that include polymeric particles containing a small molecule drug and a high molecular weight therapeutic protein. Methods of making and using the particle formulations also are disclosed.
Duquesne University

Method for preventing and/or treating insulin resistance

Described is the use of eubacterium hallii et rel. And/or alcaligenes faecalis et rel., as well as pharmaceutical, food, or feed compositions comprising these bacteria as a medicament, in particular, for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as metabolic syndrome, dyslipidemia and type 2 diabetes mellitus, as well as insulin resistance in endocrine diseases (e.g., obese subjects with type 1 diabetes mellitus, cushing's disease and lipodystrophy syndromes.
Caelus Pharmaceuticals B.v.

Diabetes biomarkers

A new markers for insulin production decline in type 1 diabetes has been found in the ratio the cd4 naïve (cd45ro−cd62l+) to central memory (cd45ro+cd62l+) and in the level of cd4 central memory t-cell subpopulations. A method of diagnosing autoimmunity and its progressiveness, more specifically diabetes, pre-diabetes, a susceptibility to diabetes mellitus, or the level of effectiveness of therapy/intervention modality for one or more of such conditions in a subject can be conducted by determining level of cd4 naïve (cd45ro−cd62l+) t-cells by immunofluorescence analysis of a sample extracted from a subject; determining level of cd4 central memory (cd45ro+cd62l+) t-cells by immunofluorescence analysis of a sample extracted from a subject, and quantitatively relating the levels of the cd4 naïve and central memory t-cells, wherein a low ratio of cd4 naïve t-cells to cd4 central memory t-cells and/or high cd4 central memory t-cell indicates autoimmunity, a susceptibility to autoimmunity, diabetes, pre-diabetes, a susceptibility to diabetes mellitus or ineffectiveness of a treatment for one or more of such conditions..
Dmnomore

Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same

Methods of identifying a subject having an autoimmune disease, such as type 1 diabetes, as likely to respond to treatment with a tumor necrosis factor-alpha (tnf-α) receptor ii activator, involving measuring cd8 protein density on the surface of autoreactive cd8+ t cells and identifying the subject as likely to respond to the treatment if the cd8 protein density is reduced relative to a reference cd8+ t cell. For type 1 diabetes, the method may involve measuring c-peptide levels in an in vitro biological sample from the subject, identifying the subject as likely to respond to the treatment if the c-peptide levels are detectable, and identifying the subject as unlikely to respond to the treatment if the c-peptide levels are substantially undetectable.
The General Hospital Corporation

Antagonist anti-il-7 receptor antibodies and methods

The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (il-7r). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids.
Rinat Neuroscience Corp.

Reverse vaccination therapy of multiple sclerosis

Disclosed are means of inducing antigen-specific tolerance through genetically modifying msc to express antigens of interest in an inducible manner or constitutive manner. Msc have been demonstrated to suppress pathological immunity in an antigen-nonspecific manner in vitro and in vivo, including clinical trials of gvhd, type 1 diabetes, and multiple sclerosis.
Creative Medical Health, Llc

Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptide

Embodiments of the present invention provide for novel therapies, pharmaceutical compositions and methods for insulin independence utilizing a new optimized hamster reg3 gamma peptide, which is new to the art and has not previously been considered for development in the 30 year history since its discovery. Methods, pharmaceutical compositions and therapies novel to the prior art are utilized in this invention to render patients with recent onset and existing type 1 diabetes insulin independent by an optimized hamster reg3 gamma peptide and an immune tolerance agent for type 1 patients to become insulin independent and used alone without an immune tolerance agent for type 2 diabetes.

Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptide

Embodiments of the present invention provide for novel therapies, pharmaceutical compositions and methods for insulin independence utilizing a new optimized hamster reg3 gamma peptide, which is new to the art and has not previously been considered for development in the 30 year history since its discovery. Methods, pharmaceutical compositions and therapies novel to the prior art are utilized in this invention to render patients with recent onset and existing type 1 diabetes insulin independent by an optimized hamster reg3 gamma peptide and an immune tolerance agent for type 1 patients to become insulin independent and used alone without an immune tolerance agent for type 2 diabetes.

Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptide

Embodiments of the present invention provide for novel therapies, pharmaceutical compositions and methods for insulin independence utilizing a new optimized hamster reg3 gamma peptide, which is new to the art and has not previously been considered for development in the 30 year history since its discovery. Methods, pharmaceutical compositions and therapies novel to the prior art are utilized in this invention to render patients with recent onset and existing type 1 diabetes insulin independent by an optimized hamster reg3 gamma peptide and an immune tolerance agent for type 1 patients to become insulin independent and used alone without an immune tolerance agent for type 2 diabetes.

Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptide

Embodiments of the present invention provide for novel therapies, pharmaceutical compositions and methods for insulin independence utilizing a new optimized hamster reg3 gamma peptide, which is new to the art and has not previously been considered for development in the 30 year history since its discovery. Methods, pharmaceutical compositions and therapies novel to the prior art are utilized in this invention to render patients with recent onset and existing type 1 diabetes insulin independent by an optimized hamster reg3 gamma peptide and an immune tolerance agent for type 1 patients to become insulin independent and used alone without an immune tolerance agent for type 2 diabetes.

Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptide

Embodiments of the present invention provide for novel therapies, pharmaceutical compositions and methods for insulin independence utilizing a new optimized hamster reg3 gamma peptide, which is new to the art and has not previously been considered for development in the 30 year history since its discovery. Methods, pharmaceutical compositions and therapies novel to the prior art are utilized in this invention to render patients with recent onset and existing type 1 diabetes insulin independent by an optimized hamster reg3 gamma peptide and an immune tolerance agent for type 1 patients to become insulin independent and used alone without an immune tolerance agent for type 2 diabetes.

Type 1 diabetes biomarkers

type 1 diabetes (t1d) patients make antibodies to self-proteins that are potential biomarkers for early detection and risk prediction. We have identified seventeen antigens as biomarkers for early diagnosis and risk prediction of t1d, including the antigens mlh1, mtif3, ppil2, nup50, tox4, fign, c9orf142, znf280d, hes1, qrfpr, ctrc, snx6, sytl4, ela2a, igrp, pax6, and hmgn3..
University Of Florida Research Foundation, Incorporated

Prevention of type 1 diabetes by treg vaccination with an insulin mimetope

The invention involves methods and products for inducing treg cells for immune suppression in connection with autoimmune disease and transplant rejection.. .

Simulation of endogenous and exogenous glucose/insulin/glucagon interplay in type 1 diabetic patients

A simulator for in-silico testing of type 1 diabetes patients uses a model that puts in relation plasma concentrations, i.e., glucose g and insulin /, with glucose fluxes, i.e. Endogenous glucose production (egp), glucose rate of appearance (ra), glucose utilization by the tissues (u), renal extraction (e), and insulin fluxes, i.e., rate of insulin appearance from the subcutaneous tissues (sc) and insulin degradation (d).
University Of Virginia Patent Foundation

Pharmaceutical composition, methods for treating and uses thereof

The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using a sglt-2 inhibitor. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions..
Boehringer Ingelheim International Gmbh

Methods, compositions, and kits for improving pancreatic beta cell viability and treating diseases or conditions related to beta cell destruction

The present disclosure provides novel methods for increasing β-cell viability in islets by delivering rlip76 polypeptides or gsta4 polypeptides, or a combination thereof; or rlip76 polynucleotides or gsta4 polynucleotides, or a combination thereof, to the islets. The disclosure also provides novel methods for treating a disease or condition in a subject, such as type 1 diabetes mellitus, by delivering rlip76 polypeptides or gsta4 polypeptides, or a combination thereof; or rlip76 polynucleotides or gsta4 polynucleotides, or a combination thereof, to islets and transplanting the islets into the subject to treat the disease or condition.
City Of Hope

Treatment of energy utilization disease

Described are compositions comprising imino sugar acids for the treatment of energy utilization disease (e.g. Metabolic syndrome, including any disease or disorder associated therewith, for example central obesity, elevated levels of triglycerides and diabetes, including type 1 diabetes, type 2 diabetes and insulin resistance), processes for producing said compositions from various plant sources, together with various products, compounds, compositions, medical uses and methods based thereon..
Summit Corporation Plc

Cxcr4 and robo1 expression as markers for autoimmune diabetes

Cxcr4 and robo-1 are biomarkers associated with type 1 diabetes. Expression of cxcr4 and robo-1 in peripheral cd3 t cells is substantially higher in patients with autoimmune diabetes (type 1 diabetes) than in non-diabetic patients.
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College

Method of predicting risk for type 1 diabetes

The present invention relates to methods, transcriptome profiles and kits useful for determining, before seroconversion, the risk that an individual will develop type 1 diabetes (t1d).. .
Turun Yliopisto

Anti-ctla4, anti-glut2 protein for the treatment of type 1 diabetes

The disclosure relates to a protein composed of a first polypeptide or polypeptide domain having a first specific binding activity for cytotoxic t-lymphocyte antigen 4 (ctla-4) expressed on a t-cell cell surface and a second specific binding activity for glucose transporter 2 (glut2) or an extracellular ectodomain thereof expressed on a pancreatic β-cell surface, wherein binding of the first polypeptide or polypeptide domain to ctla-4 induces a ctla-4 specific agonist response in the t-cell, and binding of the second polypeptide or polypeptide domain to glut2 or an ectodomain thereof does not inhibit glut2 glucose transporter function, wherein said agonist response in the t-cell induces a response that reduces immunoreactivity against pancreatic β-cells.. .
The Board Of Trustees Of The University Of Illinois

Novel uses of glp-1 receptor agonists in patients treated with insulin and/or suffering from type 1 diabetes

The present invention relates to glp-1 receptor agonists for use in hypoglycaemia or hypoglycaemic episodes in patients treated with insulin and/or suffering from type 1 diabetes, e.g. For reducing the number of hypoglycaemia or hypoglycaemic episodes..
Novo Nordisk A/s

Compositions and methods for the treatment of metabolic syndrome

The invention relates to the compounds of formula i or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i, and methods for the treatment of metabolic syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.

Substituted phenylazole derivative

Compounds are provided having an excellent hypoglycemic effect and β cell- or pancreas-protecting effects, or pharmaceutically acceptable salts thereof, and a pharmaceutical composition having an excellent therapeutic effect and/or prophylactic effect on type 1 diabetes, type 2 diabetes, and the like, which cause hyperglycemia due to abnormal glucose metabolism. A compound represented by general formula (i), or a pharmaceutically acceptable salt thereof, is disclosed..
Daiichi Sankyo Company, Limited

Crystalline anhydrate forms of a pharmaceutical

The invention provides and describes solid state 17α-ethynyl-androst-5-ene-3β,7β,17β-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol include form i anhydrate and form iv and form v solvates.
Harbor Therapeutics, Inc.

Substituted phenylazole derivative

Compounds are provided having an excellent hypoglycemic effect and β cell- or pancreas-protecting effects, or pharmaceutically acceptable salts thereof, and a pharmaceutical composition having an excellent therapeutic effect and/or prophylactic effect on type 1 diabetes, type 2 diabetes, and the like, which cause hyperglycemia due to abnormal glucose metabolism. A compound represented by general formula (i), or a pharmaceutically acceptable salt thereof, is disclosed..
Daiichi Sankyo Company, Limited

Compositions and methods for treatment of type 1 diabetes

The present invention provides compositions and methods for treating insulin-dependent diabetes mellitus in a subject comprising administration of a self-vector encoding and expressing human proinsulin.. .
Tolerion



Type 1 Diabetes topics:
  • Type 1 Diabetes
  • Type 2 Diabetes
  • Autoimmune
  • Diabetes Mellitus
  • Extracellular
  • Complication
  • Type 1 Diabetes Mellitus
  • Hyperglycemia
  • Metabolism
  • Autoimmune Disorder
  • Immune Disorder
  • Hypertension
  • Treating Diabetes
  • Impaired Glucose Tolerance
  • Immune Disease


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Type 1 Diabetes for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Type 1 Diabetes with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.3709

    file did exist - 2679

    2 - 1 - 51